CGTLive’s Weekly Rewind – July 14, 2023

Biotechs Seek Federal Coverage of Fertility Preservation Before Gene Therapy

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Haydar Frangoul, MD, Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial

Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T

Both companies have received unfavorable opinions from the Office of the Inspector General on the matter.

Ash Alizadeh, MD, PhD, professor of medicine and member, Stanford Cancer Institute

BlueRock Therapeutics Assessing the Potential of Cell Therapy for Parkinson Disease With Phase 1 Trial for Bemdaneprocel

Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.

Holistic Approaches to Treating Parkinson Disease May Be More Effective

In honor of World Brain Day, observed annually on July 22 by patient and clinician communities, CGTLive is taking a closer look at this ongoing study.

Paul Y. Song, MD, the chairman and chief executive officer of NKGen

July 21st 2024

Passage Bio Gets Positive Feedback From FDA on Plans to Test Gene Therapy PBFT02 in New Frontotemporal Dementia Indication

Paul Y. Song, MD, the chairman and chief executive officer of NKGen, discussed the potential of SNK01, the company’s autologous natural killer cell therapy, in treating PD.

William Chou, MD, the president and chief executive officer of Passage Bio

July 19th 2024

Around the Helix: Cell and Gene Therapy Company Updates – July 24, 2024

Passage Bio received the feedback on a proposal to amend the upliFT-D protocol in the context of a Type C meeting process with the FDA.

Related Content

Biotechs Seek Federal Coverage of Fertility Preservation Before Gene Therapy

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T

Both companies have received unfavorable opinions from the Office of the Inspector General on the matter.

BlueRock Therapeutics Assessing the Potential of Cell Therapy for Parkinson Disease With Phase 1 Trial for Bemdaneprocel

Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.

Holistic Approaches to Treating Parkinson Disease May Be More Effective

In honor of World Brain Day, observed annually on July 22 by patient and clinician communities, CGTLive is taking a closer look at this ongoing study.

July 21st 2024

Passage Bio Gets Positive Feedback From FDA on Plans to Test Gene Therapy PBFT02 in New Frontotemporal Dementia Indication

Paul Y. Song, MD, the chairman and chief executive officer of NKGen, discussed the potential of SNK01, the company’s autologous natural killer cell therapy, in treating PD.

July 19th 2024